Display options
Cite
Khaled HM, Abdelhamid TM, Abu-Taleb FM, et al. Impact of serum levels of IL-18 and soluble IL-2 receptor on the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP regimen. Future Sci OA. 2019;5(9):FSO414doi: 10.2144/fsoa-2019-0076.
Khaled, H. M., Abdelhamid, T. M., Abu-Taleb, F. M., El-Hifnawi, N. M., & Waley, A. B. (2019). Impact of serum levels of IL-18 and soluble IL-2 receptor on the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP regimen. Future science OA, 5(9), FSO414. https://doi.org/10.2144/fsoa-2019-0076
Khaled, Hussein M, et al. "Impact of serum levels of IL-18 and soluble IL-2 receptor on the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP regimen." Future science OA vol. 5,9 (2019): FSO414. doi: https://doi.org/10.2144/fsoa-2019-0076
Khaled HM, Abdelhamid TM, Abu-Taleb FM, El-Hifnawi NM, Waley AB. Impact of serum levels of IL-18 and soluble IL-2 receptor on the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP regimen. Future Sci OA. 2019 Aug 28;5(9):FSO414. doi: 10.2144/fsoa-2019-0076. PMID: 31608153; PMCID: PMC6787521.
Copy Download .nbib Format: NLM
Share it on

Future Sci OA. 2019 Aug 28;5(9):FSO414. doi: 10.2144/fsoa-2019-0076.

Impact of serum levels of IL-18 and soluble IL-2 receptor on the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP regimen.

Future science OA

Hussein M Khaled, Thoraya M Abdelhamid, Fouad M Abu-Taleb, Niveen M El-Hifnawi, Ahmad B Waley

Affiliations

  1. Department of Medical Oncology, National Cancer Institute, Cairo University, Egypt.
  2. Department of Medical Oncology, Faculty of Medicine, Zagazig University, Egypt.
  3. Department of Clinical Pathology, National Cancer Institute, Cairo University, Egypt.

PMID: 31608153 PMCID: PMC6787521 DOI: 10.2144/fsoa-2019-0076

Abstract

AIM & METHODS: To assess the impact of pretreatment serum levels of IL-18 and soluble IL-2 receptor (sIL-2R) on the clinical outcome of patients with diffuse large B-cell lymphoma treated with an R-CHOP protocol. Total 73 patients were included.

RESULTS: Elevated serum IL-18 (using mean as cutoff) was associated with numerically lower complete remission, and 3-year disease-free survival rates; however, the difference was not statistically significant. Nevertheless, the 3-year overall survival rates were significantly more favorable for the lower serum level group. Correspondingly, the complete remission, 3-year disease-free survival and overall survival rates for patients with low pretreatment sIL-2R levels were significantly better than individuals with higher levels.

CONCLUSION: There is a growing body of evidence supporting the utility of pretreatment serum levels of sIL-2R and IL-18 as prognostic factors in diffuse large B-cell lymphoma patients.

© 2019 Ahmad B Waley the authors.

Keywords: IL-18; diffuse large B-cell lymphoma; soluble IL-2 receptor

Conflict of interest statement

Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with th

References

  1. Leuk Lymphoma. 2019 Mar;60(3):734-741 - PubMed
  2. Cancer. 2001 Oct 15;92(8):2050-5 - PubMed
  3. Blood. 1987 Aug;70(2):396-400 - PubMed
  4. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13723-8 - PubMed
  5. Blood. 2007 Mar 1;109(5):1857-61 - PubMed
  6. Ann Hematol. 2012 May;91(5):705-714 - PubMed
  7. Leuk Res. 2017 Aug;59:20-25 - PubMed
  8. Eur J Haematol. 2011 Sep;87(3):217-27 - PubMed
  9. Acta Haematol. 2000;104(4):220-2 - PubMed
  10. Cytokine. 2012 Dec;60(3):882-9 - PubMed
  11. Leuk Lymphoma. 2016 Dec;57(12):2763-2770 - PubMed
  12. South Asian J Cancer. 2014 Jan;3(1):66-70 - PubMed
  13. Int J Cancer. 1999 Jun 21;84(3):326-30 - PubMed
  14. Cytokine. 2001 Jun 21;14(6):334-42 - PubMed
  15. Am J Hematol. 2015 Sep;90(9):790-5 - PubMed
  16. Jpn J Cancer Res. 1997 May;88(5):501-5 - PubMed
  17. Cancer Sci. 2012 Aug;103(8):1518-23 - PubMed
  18. Br J Cancer. 1998 Mar;77(6):992-7 - PubMed
  19. Oncologist. 1998;3(3):189-197 - PubMed
  20. Blood. 1988 Apr;71(4):1021-6 - PubMed
  21. J Cancer Res Clin Oncol. 2005 Feb;131(2):73-9 - PubMed
  22. J Clin Oncol. 1987 Aug;5(8):1262-74 - PubMed
  23. Genet Mol Res. 2016 Jul 29;15(3): - PubMed
  24. J Cancer Res Clin Oncol. 2009 Jan;135(1):53-9 - PubMed
  25. N Engl J Med. 1993 Sep 30;329(14):987-94 - PubMed

Publication Types